Toll-like Receptor Antagonism
Realization of the importance of abnormal TLR activation and dendritic cell dysregulation in the development of autoimmune diseases opens up the possibility of an exciting new approach for the treatment of patients with certain of these disorders. By blocking the aberrant stimulation of TLR 7, 8, and 9, the resulting downstream damaging proinflammatory activity should also be reduced or eliminated. This is goal of the Janus Biotherapeutics drug development strategy.
Janus Biotherapeutics is well positioned to develop an agent meeting these criteria. The founders and management team of the company are the discoverers, inventors, and developers of several compounds targeting TLR 7, 8, and 9, and Janus is now in the process of developing oral anti-TLR drug candidates for SLE, RA, and possibly psoriasis and Sjogren's syndrome. By blocking unwanted immune activation by these TLRs and thereby reducing downstream levels of a variety of proinflammatory factors, an anti-TLR drug should provide improved effectiveness and safety. As a convenient oral medication, it should also prove more acceptable to patients, resulting in greater adherence to treatment.